Need a little good news today? We've got plenty!
Holidash Blog

AOL Money & Finance

Posts with tag ew

Analyst upgrades, downgrades and initiations: ANF, WFMI, MIC, SNY, BMY, PFE, JNJ ...

Analyst upgrades:
  • Jefferies upgraded shares of Abercrombie & Fitch (NYSE: ANF) to Hold from Underperform on valuation. The stock has gone down 40% since they initiated coverage on September 19. The firm maintains a $29 target.
  • Citigroup upgraded EOG Resources (NYSE: EOG), Quicksilver (NYSE: KWK) and Southwestern Energy (NYSE: SWN) to Buy from Hold on their belief U.S. natural gas-focused E&P companies have near-term upside.
  • Barclays upgraded Whole Foods (NASDAQ: WFMI) to Equal Weight from Underweight citing the $425M private equity investment, which reduces liquidity risk, and its reduced cost structure.
  • Brandywine Realty (NYSE: BDN) and AvalonBay (NYSE: AVB) were upgraded to Neutral from Underperform at Merrill Lynch.
  • tw telecom (NASDAQ: TWTC) was upgraded to Neutral from Underweight at JP Morgan.
  • AmeriCredit (NYSE: ACF) was upgraded to Market Perform from Underperform at Friedman Billings.
Analyst downgrades:
  • Jefferies downgraded Macquarie Infrastructure (NYSE: MIC) to Hold from Buy to reflect the company's sensitivity to the economic slowdown and funding risk. The firm lowered their target to $9 from $40 after the company announced a dividend reduction.
  • Sanofi-Aventis (NYSE: SNY) was cut to Sell from Neutral at UBS due to the company's exposure to potential generic competition and a lack of new products.
  • Friedman Billings downgraded Cleveland Cliffs (NYSE: CLF) to Market Perform from Outperform and lowered their target to $42 from $50 to reflect the risk of further production cuts.
  • Credit Suisse lowered Acme Packet (NASDAQ: APKT) to Neutral from Outperform.
  • Delta Petroleum (NASDAQ: DPTR) was downgraded at Deutsche Bank to Sell from Hold.
  • Siemens (NYSE: SI) was downgraded to Sell from Buy at UBS.
Analyst initiations:
  • Goldman initiated Bristol-Myers (NYSE: BMY) with a Buy rating and $27 target as they believe it is making progress in becoming a mid-sized specialty biopharmaceutical company. The firm expects the company to be active in M&A and to spin-off or divest its slow-growth or fast-growing assets, such as virology and oncology.
  • Goldman believes Pfizer (NYSE: PFE) needs a "radical transformation" and restructuring that includes a break up, spin and merger in order to outperform over the next several years. Shares were assumed with a Sell rating and $19 target.
  • Johnson & Johnson (NYSE: JNJ) was initiated with a Neutral rating and $65 target at Banc of America. The firm prefers to be on the sidelines given uncertainties surrounding 2009 revenue growth and the potential for negative rhetoric out of Washington on pharma costs.
  • Acorda (NASDAQ: ACOR) was started at RBC Capital with an Outperform rating and $30 target.
  • Cavium Networks (NASDAQ: CAVM) and NetLogic (NASDAQ: NETL) were initiated with Neutral ratings at Cowen.
  • Edwards Lifesciences (NYSE: EW) was assumed with a Buy rating and $61 target at Piper Jaffray.

Edwards Lifesciences (EW): Price cycles in bullish 'flag' formation

Edwards Lifesciences Corporation (NYSE: EW) provides products and technologies designed to treat cardiovascular diseases. Offerings include tissue heart valves, valve repair products, heart monitoring equipment, central venous access devices and cardiac surgery system products. The company sells its goods through a direct sales force and independent distributors worldwide. Formerly part of Baxter International (NYSE: BAX), the firm was a year 2000 spin-off.

Edwards surprised the Street late last month, when it reported Q1 EPS of 56 cents and revenues of $296.8 million. Analysts had been expecting 49 cents and $284.4 million. In discussing the results, the CEO noted the success of new products and strong international sales growth. Management also guided Q2 EPS to 62-66 cents (58 cent consensus), FY08 EPS to $2.45-$2.53 ($2.35 consensus) and FY08 revenues to $1.210-$1.260 billion ($1.18B consensus).

Continue reading Edwards Lifesciences (EW): Price cycles in bullish 'flag' formation

Analyst initiations: Medical supples and devices sector, EWBC, TPX and ABH

MOST NOTEWORTHY: The medical supplies and devices sector, East West Bancorp, Tempur Pedic and AbitibiBowater were today's noteworthy initiations:
  • Credit Suisse initiated the medical supplies and devices sector with a Market Weight rating and started shares of Edwards Lifesciences (NYSE: EW) and Becton, Dickinson and Co (NYSE: BDX) with Outperform ratings and Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX) with Neutral ratings.
  • East West Bancorp (NASDAQ: EWBC) was initiated with a Buy rating and $36 target at B. Riley; the firm's target implies a 23.1% potential total return over the next twelve months including the stock's 1.35% dividend yield.
  • Tempur Pedic (NYSE: TPX) was started with an Outperform rating at William Blair, as they find the current valuation attractive for long-term investor given the company's strong position in the specialty sleep products.
  • Deutsche Bank resumed coverage of AbitibiBowater (NYSE: ABH) with a Hold rating and $29 target, citing the strength of the Canadian dollar and difficult newsprint fundamentals.
OTHER INITIATIONS:

Analyst upgrades: PII, EW, BE and FORSY

MOST NOTEWORTHY: Polaris Industries, Edwards Lifesciences, BearingPoint and Fortis were today's noteworthy upgrades:
  • Rochdale upgraded Polaris Industries (NYSE: PII) to Buy from Hold, as they have increased confidence in the company's ability to achieve estimates.
  • Piper upgraded shares of Edwards Lifesciences (NYSE: EW) as they believe the bad news is behind the company with a U.S. turnaround expected in 2008.
  • Jefferies raised shares of BearingPoint (NYSE: BE) to Hold from Underperform on valuation as they believe the risk/reward is neutral following the recent pullback.
  • Fortis (OTC: FORSY) was upgraded to Outperform from Peer Perform at Bear Stearns. The firm upgraded shares on valuation as they believe the recent weakness is overdone.
OTHER UPGRADES:

Analyst downgrades 3-08-07: TiVo finds competiton growing

MOST NOTEWORTHY: Some of today's more notable downgrades included Apartment Investment & Management Co (AIV), Weyerhaeuser Company (WY) and Edwards Lifesciences Corp (EW).
  • RBC downgraded Apartment Investment & Management Co (NYSE: AIV) to Underperform from Sector Perform based on valuation and concerns regarding the company's transaction focus.
  • Weyerhaeuser Co (NYSE: WY) was downgraded at BMO to Underperform from Market Perform based on valuation.
  • Morgan Stanley downgraded Edwards Lifesciences (NYSE: EW) to Underweight from Equal-Weight based on increased competition and aggressive Street estimates for the downgrade.
OTHER DOWNGRADES:
  • William Blair downgraded TiVo Inc (NASDAQ: TIVO) to Market Perform from Outperform citing slowing customer growth, competition, rising subscriber acquisition costs and valuation.
  • Canccord cut Hollis-Eden Pharmaceuticals Inc (NASDAQ: HEPH) to Hold from Buy following the cancellation of the ARS contract.
  • Morgan Stanley downgraded Cymer, Inc (NASDAQ: CYMI) to Underweight from Equal-Weight.
  • Baird cut Genesco Inc (NYSE: GCO) to Neutral from Outperform following lowered guidance.
  • Merriman cut Distributed Energy Systems Corp (NASDAQ: DESC) to Neutral from Buy following the company's lower-than-expected Q4 revenues.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Symbol Lookup
IndexesChangePrice
DJIA-215.458,376.24
NASDAQ-46.821,445.56
S&P 500-25.52845.22

Last updated: December 05, 2008: 12:04 AM

BloggingStocks Exclusives

Hot Stocks

BloggingStocks Featured Video

TheFlyOnTheWall.com Headlines

WalletPop Headlines

AOL Business News

Latest from BloggingBuyouts

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance